AH
MCRB icon

Achievement Holdings’s Seres Therapeutics MCRB Stock Holding History

Achievement Holdings’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-650
Closed -$540 – 216
2015
Q2 		$540 Buy
+650
New +$567K 0.02% 196

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Achievement Holdings's MCRB Position: Q3 2015 in Review

Achievement Holdings sold out of Seres Therapeutics (MCRB) in Q3 2015, closing a stake of 650 shares — an estimated $540 sold.

Achievement Holdings first reported a position in MCRB in Q2 2015 and held it in 1 quarter. The position peaked at $540 in Q2 2015. 60 funds tracked by Wall St. Rank hold MCRB as of Q3 2015.

  • Achievement Holdings reported no remaining Seres Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Achievement Holdings sold 650 Seres Therapeutics shares in Q3 2015, an estimated $540.
  • Achievement Holdings first reported a position in Seres Therapeutics in Q2 2015 and held it in 1 quarter.
  • Achievement Holdings's Seres Therapeutics position peaked at $540 in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2015.

Based on Achievement Holdings's 13F filing for Q3 2015, filed 16 Nov 2015.